Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

被引：7

作者：

Kim, Hyun Jin ^{[1
]}

Park, Seok O. ^{[2
]}

Ko, Seung-Hyun ^{[3
]}

Rhee, Sang Youl ^{[4
]}

Hur, Kyu-Yeon ^{[5
]}

Kim, Nan-Hee ^{[6
]}

Moon, Min Kyong ^{[7
]}

Lee, Byung-Wan ^{[8
]}

Kim, Jin Hwa ^{[9
]}

Choi, Kyung Mook ^{[6
]}

机构：

[1] Chungnam Natl Univ, Div Endocrinol & Metab, Dept Internal Med, Sch Med, Daejeon, South Korea

[2] Gwangmyeong Sungae Hosp, Dept Internal Med, 36 Digital Ro, Gwangmyeong 14241, South Korea

[3] Catholic Univ Korea, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[4] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul, South Korea

[5] Sungkyunkwan Univ, Samsung Med Ctr,Sch Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea

[6] Korea Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[7] Seoul Natl Univ, Dept Internal Med, Seoul Metropolitan Govt Boramae Med Ctr, Coll Med, Seoul, South Korea

[8] Yonsei Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[9] Chosun Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Gwangju, South Korea

来源：

DIABETES & METABOLISM JOURNAL | 2017年 / 41卷 / 06期

关键词：

Cardiovascular benefit; Clinical practice guideline; Combination therapy; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Monotherapy; RANDOMIZED CONTROLLED-TRIAL; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN GLARGINE; PHARMACOLOGICAL MANAGEMENT; DOUBLE-BLIND; EFFICACY; SAFETY; LIRAGLUTIDE; METFORMIN; DULAGLUTIDE;

D O I：

10.4093/dmj.2017.41.6.423

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

引用

页码：423 / 429

页数：7